Genetikk Flashcards

(37 cards)

1
Q

Genetic life time prevalence

A

3,4-7,3 %

Phenotype description, molecular basis known: 5625

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Allel

A

One of several alternative forms of a gene
In the 22 pair of autosomes, you have 2 alleles; one from mom and one from dad
A/a = Heterozygous
A/A or a/a = Homozygous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Polymorphism

A

a genetic variant that is conserved in the population, and has an allele frequency of ≥ 1%.
Common genetic variants.
Over 340 mill known Single Nucleotide Polymorphisms (SNPs) in the human genome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mutasjoner:

Most chromosome abnormalities (aneuploidies, translocations, deletions, duplications) have no previous family history.

Prevalence of chromosomal abnormalities
• Newborns: 0.5%
• Stillborns: 5%
• Spontaneous abortions, 1st trimester: 50%

• Robertsonian translocation (between acrocentric chromosomes). Balanced carriers: 1/1000

A

Kromosomal: Numerical alterations
e.g. monosomy, trisomy, triploidy

Regional: Deletions, duplications, translocations.

Gen:
- Punktmutasjoner; Deletion and insertion of one or more nucleotides. Missense, nonsense, splice site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Missense mutation

A

One aa is replaces by another one

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Nonsense mutation

A

an aa codon is replaced by a stop codon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Frameshift mutation

A

Deletion (or insertion) of a base resulting in a shift in all subsequent codons)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Splice site = no splicing

A

Leads to «exon-skipping» and deletions at the mRNA

level.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

DNA analysis:

to detect changes that are not visible under an optical microscope

A

• PCR (Polymerase Chain Reaction)

• MLPA (Multiplex Ligation-dependent Probe Amplification) used for Deletion and Duplications.
Eks:
Duchenne muscluar dystrophy (deletion) Charcot Marie Tooth disease.

• SNP- array (single nucleotide polymorphism)

• DNA Sequencing. Can detect any point mutation
and small deletion/insertion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Classical Mendelian inheritance
• Autosomal recessive
• Autosomal dominant
• X-linked inheritance

A

Non Mendelian inheritance

• Mitochondrial inheritance, from mother

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pedigree (genogram)

A

Is a family tree showing the pattern of inheritance for a specific phenotypic trait

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Autosomal (ikke kjønnsbundet) recessive diseases

  • Healthy parents may have one or more affected children.
  • Men and women are affected equally often.
  • The parents of an affected child are obligate carriers.
  • Each of their children has a 25% risk of inheriting the disease.
  • Each healthy sibling of an affected child has a 67% risk of being a carrier.
    Mor og far må begge være bærere: 1 unge får sykdommer, 2 blir bærere, 1 blir frisk. Så 2/3 = 67% bærere.

• The affected gene resides on one of the 22 autosomal chromosomes.

A

Examples:

  • Cystic fibrosis is a disease caused by “thick mucous”: mucoviscidosis; chronic lung infection !!
    pancreatic insufficiency – malabsorption, increased CHLORIDE concentration in sweat !!
    More than 1500 known mutations. Most frequent mutation is del F508 (Phe508).
  • Phenylketonuria (PKU) (Følling’s disease)
    Neonatal screening Caused by mutations in the PAH gene (Phenylananine hydroxylase).
    Phenylalanine accumulates in the body fluid and damages the developing CNS.
    Therapy: Restricted dietary intake of phenylalanine.
  • Spinal muskel atrofi: 1/30-40 er bærere
    SMA-1, onset før 6 måneder, death before 2 years
    SMA-2, onset 6-18 måneder, 70% overlever til 25 år.
    Behandling: Nusinersen: Spinraza

In total over 2000 autosomal recessive diseases, including many congenital metabolic diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Autosomal (ikke kjønnsbundet) dominant disorders

  • Each child of an affected person has a 50% risk of inheriting the disease
  • Occurs in each generation. Often late onset.
  • Men and women are affected equally often. Male-to-male transmission occurs, which is an important way of distinguishing these disorders from X-linked recessive disorders.
  • Penetrance; is the proportion of individuals with the mutation who exhibit clinical symptoms.
  • Expressivity; is the variations in a phenotype among individuals carrying a particular genotype.

• Autosomal dominant disorders may be caused by new mutations (relatively rare) originating from germline mosaicism in one of the parents or from early embryonic mutations in the offspring.

A

Examples:

  • Huntington’s disease; neurodegenerative
  • Marfan syndrome; connective tissue disorder
  • Colon polyps; origin of colon cancer
  • Myotonic dystrophy; progressing muscular dystrophy

More than 2600 known autosomal dominant diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

X-linked recessive disorders

  • Mainly affecting men!
  • Diseases are transmitted by healthy* mothers
  • Heterozygous women are generally unaffected. Exceptions: skewed X inactivation, monosomy X (Turner)
  • All daughters of any man with the disease become carriers. Each of his daughters’ sons has a 50% risk of inheriting the disease
  • Not transmitted from father to son.
  • Can be transmitted unrecognized via several female carriers
A

Examples:

• Haemophilia type A and B

• Duchenne muscular dystrophy
1/ 3500 boys, very few girls

• Fragile X syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mitochondrial inheritance

  • Caused by mutations in mtDNA
  • Inherited from mother to child; maternal inheritance (sperms do not transmit mitochondria)
  • Low incidence
  • Affects both sexes
A

Examples:

– Lebers’ inheritable optic neuropathy (LHON)

– Inheritable hearing impairment

• Most proteins in mitochondria are encoded by nuclear genes. Mutations in these genes may cause mitochondrial disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

The genetic consultation

Laboratory analyses

1) Chromosome analysis

I. Traditional chromosome analysis (G-band, living cells)

A

• Chromosomes only visible in dividing cells

• Living cells from different tissues cultured to divide
– Blood lymphocytes (Na-heparin sample)
– Skin fibroblasts (or achilles tendon biopsy)
– Amnion - amniocytes
– Chorionic villi biopsy - fetal cells

  • Culture cells, make them divide
  • Arrest cells, metaphase
  • Stain with ie Giemsa = G-band preparation
  • Microscope (11 cells or more)
  • 2-3 weeks for result
17
Q

III. QF-PCR
Quantitative Fluorescence–Polymerase Chain Reaction

DNA based, RAPID test for aneuploidies
– 1-2 days
Amplifies amount of DNA in specific regions
– Quantifies chromosomes 13, 18, 21, X, Y

A

Indications for chromosomal analyses

• G-band analysis
– 3 or more spontaneous abortions or infertility.
– Suspected structural chromosomal aberration.
– Suspected sex chromosome abnormality (growth, pubertal development)

• QF-PCR including sex chromosomes
– Prenatal diagnostics
– Learning difficulty

• SNP array
– Intellectual disability, severe autism
– Congenital malformations – major, or several minor

18
Q

IV. Chromosomal microarrays

• Submicroscopic (< 5-7 Mb) chromosomal aberrations by DNA based methods.

• Several names/methods
– (Genomic) Copy number analysis («kopitallsanalyse»)
– Array CGH (comparative genome hybridisation)
– SNP array (Single Nucleotide Polymorphisms)
– «Matrisebasert kopitallsundersøkelse»

A
  • Detects deletions, duplications
  • NB! Normal variation
  • Indications: ID, (multiple) malformations, syndromes,…
  • Probably replacing most traditional G-band analyses
  • Detects only unbalanced abnormalities
19
Q

Aneuploid = Extra/missing single/few chromosomes

  • Monosomy (e.g. 45, X)
  • Trisomy (e.g. 47, +21)
  • Sex chromosomes or autosomes
A

Euploid = Extra set(s) of chromosomes

– Polyploidy (e.g. triploidy 69, XXX)
– Not compatible with life (but occurs at conception, or mosaic)

20
Q

Klinefelter syndrome (Høy)
- 47, XXY
(48, XXXY etc)

Turner syndrome, 45, XO (Lav)

A

Congenital anomalies:

• Major congenital anomaly: 2-3% newborns

21
Q

Huntington disease

  • Irregular involuntary movements (chorea)
  • Cognitive and mental changes
  • Dementia
  • Gradual weight loss
  • Appears in adulthood
  • Risk of early/serious illness if inherited from father
  • Autosomal dominant inheritance

• CAG repeat expansion of exon 1 in HTT gene; polyglutamine tract
– normally: < 26
– Intermediate 27-35
– w/ reduced penetrance 36-39
– Full penetrance > 40
– Juvenile > 60 (rare, usually from father)

A

Myotonic dystrophy –> Maternal transmission!
• Atrophy (dystrophy): face, distal in upper and lower extremities
• Myotonia: inability of the muscles to relax after contraction (EMG)
• Cataracts
• Frontal balding
• Endocrine symptoms / gastrointestinal / cardiac
• Mental retardation can occur
• Autosomal dominant inheritance

• Type 1: CGG repeats ”in ” DMPK gene:
– Normal 5-34 
- premutation 35-49
– Mild 50-150 
- classic 100- 1000; RNA disturbance
– Congenital (from mother) > 1000

• Type 2: CCTG repeat expansion in intron 1 of CNBP
– No anticipation No congenital presentation
– Extreme somatic instability, RNA disturbance

22
Q

Genomic imprinting:

  • Normal development requires the complementary presence of both maternal and paternal genetic material.
  • An imprinted gene will be inactivated (turned off) and therefore not be expressed during gametogenesis in individuals of one sex, whereas in the opposite sex it will be expressed.
A

Examples of genomic imprinting:

  • Prader-Willi
    • neonatal hypotonia ”floppy infant”
    • failure to thrive, feeding difficulties
    • later on; excessive eating (insatiable appetite, aldri mett)
    • slight mental retardation
    • MLPA Methylation testing: > 99%
    – paternal deletion 15q11-q13
- AngelMan syndromes
• Normal at birth
• Seizures w/ specific EEG pattern? 
• microcephaly – 50% by 12 months 
• Ataxia
• Mental retardation
• MLPA Methylation testing ~ 80%
– maternal deletion of 15q11-q13
23
Q

Duchenne MD (DMD):

• CK: >10x normal , almost complete lack of dystrophin in biopsy.
• Clinical onset at the age of 2-3 with progressive proximal muscle weakness (lower extremities).
• Historically premature death around the age of 20
– (cardiomyopathy, respiratory problems)

  • Hypertrophy of calves (tykke legger)
  • Gowers sign, holder seg til knærne når røyser seg opp.
A

BeckerMD (BMD):

  • CK: >5x normal, reduced dystrophin in biopsy
  • Greater clinical variation and later onset
24
Q

Hereditary cancer
• 5-10 % of all cancers

  • Germline (mostly inherited) mutations in:
  • Tumor suppressor genes (common cause):
  • Negative regulate cell cycle
  • «Loss of function» mutations
  • Two hit.
  • BRCA1/2, TP53, RB1, APC

• Proto-oncogenes (rare cause):

  • Positive regulate cell cycle
  • «Gain of function » mutations
  • One hit.
  • RET (MEN2B).

But cancer is common – > 40% of aging population

A

Knudson 2 hit hypothesis:

Both copies of the gene must be knocked out in order to cause malignancy.

Sporadic cancer: 2 acquired mutations

Hereditary cancer: 1 acquired mutation, 1 inherited

Familial cancer is caused by?
- A germline mutation plus a somatic mutation in affected tissue.
Heterozygosity of mutation (inherited via germline) in a tumour- suppressor gene.
A second hit on the other allele (in somatic tissue) is required for tumour formation.

25
Proto-oncogenes - Positively regulate the cell cycle - Activating mutations «One hit». «Gain of function».
Tumor-suppressor genes (TSGs) - Negatively regulate the cell cycle - Inactivating mutations
26
HEREDITARY CANCER * Germline mutation (1. hit) * Somatic mutations (2. hit) * Bilateral * Early onset * Multiple tumors * Combination of genetically «related» cancers on the same side of the family * Rare tumors
SPORADIC CANCER * Somatic mutation (1. hit) * Somatic mutations (2. hit) * Unilateral * Later onset * Single tumors
27
Diagnostic, incident testing; by treating clinicians * Female breast cancer < 60 years of age * Male breast cancer regardless of age * Ovarian cancer regardless of age
Healthy persons with 1st degree relative (or 2nd degree with a male between) with one of the following: • Female breast cancer < 50 • Male breast cancer (any age) • Female breast cancer, triple negative < 60 (østrogen, progersteron, herceptin-2) • Female breast cancer, bilateral < 60 • Ovarian cancer • 2 first degree relatives mean age < 55 (breast / prostate) • 3 first degree relatives with breast cancer (any age)
28
Lynch syndrome (HNPCC) hereditary non-polyposis colorectal cancer) • Autosomal dominant, reduced penetrance (=risk). • Increased cancer risk; - Colorectal cancer (CRC) – up to 70 % - Endometrial cancer – up to 50% • MMR (mismatch repair): MLH1, MSH2, MSH6, PMS2, EPCAM + Better prognosis of cancer disease, often cancer surviviors and more than one cancer diagnosis.
Surveillance: * Colonoscopy every second year from age 25. * Gynecological examination (endometrialbiopsy if indicated) yearly from age 30. Risk reducing surgery? • Prostate examination + PSA from age 40 • Urine stix from age 30 (screening for hematuria)
29
Familial Atypical Multiple Mole Melanoma Syndrome • Autosomal dominant, reduced penetrance (=risk). • Increased cancer risk; • Malignant melanoma (MM) –30-90% • Pancreatic cancer –15-25% • CDKN2A, CDK4 + more • Risk increases with UV light exposure, and depend on place of residence and family history.
Surveillance: * Dermatologist examination yearly from 18-20, or earlier based on age of onset MM in the family. * Pancreatic surveillance NOT effective/available. * SUN protection!
30
FAP (familial adenomatous polyposis) * >100, often thousands adenomatous colon polyps at a young age. * Autosomal dominant, 20 % de novo; APC- gene * High risk of early onset colorectal cancer (near 100 % risk by 50 years) * Risk of: duodenal cancer, thyroid cancer, desmoid tumors, CHRPE.... ++++
Prevention/screening: * Rectoscopy / coloscopy from the age of 10 * Total colectomy (from late teens) • Polyps also occur in the stomach and the duodenum
31
Prenatal screening: large populations, low risk, affordable non-invasive methods.
Prenatal diagnosis: selected groups, high risk, severe conditions invasive procedures.
32
Screening - various definitions: * Sequential (stepwise) screening = provision of an initial set of tests followed by another set usually for those at LOW or intermediate risk * Contingency screening = provision of an initial set of tests followed by another set only for those initially found to be at INTERMEDIATE risk * “Secondary” screening = a follow-up screening test for those women who were POSITIVE by an initial primary test
Detection rate (sensitivity) False positive rate (1-specificity) Odds of being affected given a positive result (OAPR) The ratio of affected to unaffected cases (usually 1:n) TP:FP (true positive / fake positive)
33
Invasive procedures • Amniocentesis (AC): amniotic fluid withdrawal - from 15th week of pregnancy • Chorionic villus sampling (CVS): placental biopsy - From 10th week of pregnancy Other invasive methods • Cordocentesis: blood sample from the umbilical cord – 18th week of pregnancy * Foetoscopy * Fetal skin-biopsy, liver biopsy
Amniocentesis: • Aseptic • Fetus and placenta located using ultrasound • Transabdominal • 15 ml amniotic fluid • Cytogenetic investigations – RAD: rapid analysis of selected chromosomes (13, 18, 21): 2-3 days (QF-PCR) – CMA (chromosomal microarray): 10 days • Procedure rel. risk of miscarriage < 0.5% CVS: • Aseptic • Fetus and placenta located using ultrasound • Transabdominal (rarely transcervical) • 5-10 mg placental tissue • Karyotype: direct (– under 24 hrs) • Long-term culture: 1-2 weeks • Procedure related risk of miscarriage: 0,2-0,7 % (1. trimester) • Fetomaternal bleeding (anti-D prophylaxis) • Suitability for DNA analysis
34
Preimplantation Genetic Diagnosis (PGD) • when one or both genetic parents has a known genetic abnormality and testing is performed on an embryo to determine if it also carries a genetic abnormality. • look for spesific diseases Testing: • technique used to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy. • the procedure carries a risk of wrong diagnosis (technical, mosaicism).
Preimplantation genetic diagnosis (PGD) | is NOT allowed performed in Norway.
35
Aneuploidy screening tests / Non-Invasive Prenatal Testing = NIPT ``` = Risk asessement • Ultrasound scan (early gestational age: Nuchal translucency. NT > 2,8 --> økt risiko for Downs) • Maternal biochemical serum markers (double test: B-hCG og PAPP-A). Combined tests (CUB) w/ USS. • Analysis of cell free DNA (fetal DNA circulating in maternal blood) • Cell-based NIPT ``` ``` False positives • Few but important! - Confined Placental Mosaicism - Vanishing twin (when used in early pregn) - Maternal chromosomal abberations - Maternal cancer ```
First trimester combined test (CUB) • The hCG and PAPP-A levels, along with the maternal age and size of the nuchal translucancy gives a risk assessement of the common aneuploidies (trisomy 21, 18 and 13). • Performed in week 11/12-13+6 of pregnancy (CRL 45-84 mm) CUB- performance Trisomi 21 • Detection rate : 82-87 % ``` NIPT- performance T21, T13 and T18 • PPV T21: 98% ! • PPV T18: 92% • PPV T13: 69% • Sensitivity : 97,3-99,5% • Spesificity : 99,7-99,9% very few false negatives! ``` ``` USS: Ultrasound scan • Structural malformations (isolated/multiple) • ”Soft signs” mainly indicative of trisomy (?) Nuchal Translucency measurements Nasal Bone presence Nasal Bone Length Short Femoral Length Echogenic Intracardiac Focus Hydronephrosis SUA..etc ```
36
Cell free (cf) fetal DNA in maternal plasma * First discovered by Dennis Lo et al (1997) * Circulating free DNA is either maternal or fetal * Originates from placenta (apoptotic trophoblast) * Detectable from 4th week * Generally 10-20% of total cfDNA present in a sample (variable) * Amount approximately constant in the late first trimester through the second trimester * % increases with gestation
Differences in testing policies for laboratories offering cf-DNA screening * Minimum fetal fraction (e.g. >4%, >2.8%, or not measured) * Gestational age (>9 weeks, >10 weeks) * Testing for DZ twins (including or excluding sex chromosome abnormalities) * Surrogate mother * Inclusion of diandric triploidy, molar pregnancy * Inclusion of maternal age in the algorithm * Reporting differences; use of a “patient specific risk score”, “positive” “aneuploidy detected,” “aneuploidy suspected (borderline value),” or “personalized risk’’. * NIPT screening also for other disorders ! (some microdeletion syndromes, other rare autosomal trisomies, partial imbalances) Cell-free DNA screening tests for microdeletions have NOT been validated clinically and are NOT recommended at this time “ ACOG 2016
37
Quadrupel screen: Utenom PAPPA-A * Beta-hCG (høy ved Downs) * AFP (lav ved Downs, høy ved Spina bifida) * Estriol (lav ved Downs) * Inhibin-A (høy ved Downs) Second trimester Quadruple test = AFP, hCG, uE3, INH-A at 15-20 weeks Triple test (rarely used in Norway) • Performed in week 15-17 of pregnancy • Blood test :AFP, hCG and estriol (Ikke Inhibin A)
.